Concord Biotech CEO, chairman, board of directors and AGM

Each resolution counts the houses whose vote was matched to it; the rest are listed last.

• ADOPTION OF THE ANNUAL AUDITED STANDALONE AND CONSOLIDATED FINANCIAL STATEMENTS AND REPORTS THEREON

  ›Against Angel One Mutual Fund, Groww Mutual Fund, Invesco Mutual Fund, Motilal Oswal Mutual Fund, Navi Mutual Fund, Zerodha Mutual Fund

  • Angel One Mutual FundNon-disclosure of the audited financial statements of Subsidiary on the website of the Company.
  • Groww Mutual Fund, Invesco Mutual Fund, Motilal Oswal Mutual Fund, Navi Mutual Fund, Zerodha Mutual FundUnqualified financial statements. Non-Compliant with S. 136(1) of the Companies Act & Regulation 46(2)(s) of SEBI LODR: Nondisclosure of the audited financial statements of Subsidiary on the website of the Company.

  16 for6 against
• DECLARATION OF DIVIDEND

  22 for0 against
• APPOINTMENT OF A DIRECTOR IN PLACE OF ONE RETIRING BY ROTATION

  16 for0 against
• APPOINTMENT OF MRS. EKTA GUPTA AS AN INDEPENDENT DIRECTOR OF THE COMPANY

  23 for0 against
• APPROVAL OF ENHANCED LIMITS FOR ADVANCING LOANS, PROVIDING GUARANTEES AND SECURITIES TO SUBSIDIARY, ASSOCIATE AND JOINT VENTURE COMPANIES PURSUANT TO SECTION 185 OF THE COMPANIES ACT, 2013

  ›Against Angel One Mutual Fund, Axis Mutual Fund, Bandhan Mutual Fund, Canara Robeco Mutual Fund, Edelweiss Mutual Fund, Groww Mutual Fund, ICICI Prudential Mutual Fund, Invesco Mutual Fund, Jio BlackRock Mutual Fund, Kotak Mahindra Mutual Fund, Mirae Asset Mutual Fund, Motilal Oswal Mutual Fund, Navi Mutual Fund, quant Mutual Fund, UTI Mutual Fund, Zerodha Mutual Fund

  • Angel One Mutual FundThe Company has not made adequate disclosures as required under ISF standards.Inadequate disclosures regarding the particulars mandated u/s 185 of Companies Act, 2013 Transparency Concerns: Further, the Company should provide clarity with regards to the capacity to meet the proposed Related Party Transaction obligations by the related parties involved. Transparency & Governance concern: The Company has not made adequate disclosures as to how the rate of interest charged by the Company is at arm’s length basis. No clarity regarding how other shareholders of the entities which are involved in the transaction will contribute. The Company has not disclosed specific details of entities with which the Company is transacting. No clarity with regards to obtaining prior approval of shareholders. The Company has not aggregated the previous transactions entered with Joint venture which includes sales in the current proposal.
  • Axis Mutual FundThe company proposes to give loans/guarantees or provide security to subsidiaries, associates or joint ventures of the company. The approval is enabling in nature. There is no clarity whether the financial support will be to the extent of shareholding. The company must disclose granular details including names of these companies and entities, details of other shareholders (other than that of Concord Biotech), the nature and size of their operations and terms of support, whether the financial support is to the extent of the company’s shareholding and rationale, to enable shareholders to make an informed decision. Further, it appears that the company is also seeking approval for the proposed transactions as a related party transaction: we expect granular details while reviewing RPTs, including tenure of the approval. Given the lack of clarity, we are unable to support the resolution.
  • Bandhan Mutual Fund, Edelweiss Mutual Fund, Groww Mutual Fund, Invesco Mutual Fund, Motilal Oswal Mutual Fund, Navi Mutual Fund, Zerodha Mutual FundNon-Compliant with SEBI LODR Regulations: The Company has not disclosed period for which Omnibus approval is sought. NonCompliant with ISF standards: The Company has not made adequate disclosures as required under ISF standards. Non- Compliant with Companies act: Inadequate disclosures regarding the particulars mandated u/s 185 of Companies Act, 2013 Transparency Concerns: Further, the Company should provide clarity w.r.t. the capacity to meet the proposed RPT obligations by the related parties involved. Transparency & Governance concern: The Company has not made adequate disclosures as to how the rate of interest charged by the Company is at arm’s length basis. No clarity regarding how other shareholders of the entities which are involved in the transaction will contribute. The Company has not disclosed specific details of entities with which the Company is transacting. No clarity with regards to obtaining prior approval of shareholders. The Company has not aggregated the previous transactions entered with Joint venture which includes sales in the current proposal.
  • Canara Robeco Mutual Fund, Jio BlackRock Mutual FundThe company proposes to give loans/guarantees or provide security to subsidiaries, associates or joint ventures of the company. The approval is enabling in nature. There is no clarity whether the financial support will be to the extent of shareholding. The company must disclose granular details including names of these companies and entities, details of other shareholders (other than that of Concord Biotech), the nature and size of their operations and terms of support, whether the financial support is to the extent of the company’s shareholding and rationale, to enable shareholders to make an informed decision.Further, it appears that the company is also seeking approval for the proposed transactions as a related party transaction: we expect granular details while reviewing RPTs, including tenure of the approval. Given the lack of clarity, we are unable to support the resolution.
  • ICICI Prudential Mutual FundThe company proposes to give loans/guarantees or provide security to subsidiaries, associates or joint ventures of the company. The approval is enabling in nature. There is no clarity whether the financial support will be to the extent of shareholding. The company must disclose granular details including names of these companies and entities, details of other shareholders (other than that of Concord Biotech), the nature and size of their operations and terms of support, whether the financial support is to the extent of the company’s shareholding and rationale, to enable shareholders to make an informed decision. Further, it appears that the company is also seeking approval for the proposed transactions as a related party transaction: we expect granular details while reviewing RPTs, including tenure of the approval. Given the lack of clarity, the AMC has voted against the resolution.
  • Kotak Mahindra Mutual FundThe company proposes to give loans/guarantees or provide security to subsidiaries, associates or joint ventures of the company. The approval is enabling in nature. There is no clarity whether the financial support will be to the extent of shareholding. The company must disclose granular details including names of these companies and entities, details of other shareholders (other than that of Concord Biotech), the nature and size of their operations and terms of support, whether the financial support is to the extent of the company s shareholding and rationale, to enable shareholders to make an informed decision. Further, it appears that the company is also seeking approval for the proposed transactions as a related party transaction: we expect granular details while reviewing RPTs, including tenure of the approval. Given the lack of clarity, we are unable to support the resolution.
  • Mirae Asset Mutual FundAs per advisory recommendation (passive holding)
  • quant Mutual FundNon-compliant with SEBI LODR regulations: The company has not disclosed period for which omnibus approval is sought. Non-compliant with ISF standards: The company has not made adequate disclosures as required under ISF standards. Non-compliant with Companies act: Inadequate disclosures regarding the particulars mandated u/s 185 of Companies Act, 2013. Transparency concerns: Further, the company should provide clarity w.r.t. the capacity to meet the proposed RPT obligations by the related parties involved. Transparency & governance concern: The company has not made adequate disclosures as to how the rate of interest charged by the Company is at arm’s length basis. No clarity regarding how other shareholders of the entities which are involved in the transaction will contribute. The Company has not disclosed specific details of entities with which the Company is transacting. No clarity with regards to obtaining prior approval of shareholders. The Company has not aggregated the previous transactions entered with Joint venture which includes sales in the current proposal.
  • UTI Mutual FundThe company proposes to give loans/guarantees or provide security to subsidiaries, associates or joint ventures of the company. The approval is enabling in nature. There is no clarity whether the financial support will be to the extent of shareholding. The company must disclose granular details including names of these companies and entities, details of other shareholders (other than that of Concord Biotech), the nature and size of their operations and terms of support, whether the financial support is to the extent of the company’s shareholding and rationale, to make an informed decision. Further, it appears that the company is also seeking approval for the proposed transactions as a related party transaction: we expect granular details while reviewing RPTs, including tenure of the approval. Given the lack of clarity, we are unable to support the resolution.

  6 for16 against
• RATIFICATION OF REMUNERATION OF COST AUDITORS

  23 for0 against

Each resolution counts the houses whose vote was matched to it; the rest are listed last.

• To receive, consider, approve and adopt the Audited Standalone and Consolidated Financial Statements for the financial year ended on 31st March, 2025 together with the Auditor and Directors Report thereonMoreLess

  23 for0 against
• To declare dividend for the financial year 2024-25.

  19 for0 against
• To appoint Mr. Rajiv Agrawal (DIN: 00379990) who retires by rotation and being eligible offers himself for reappointment as Director

  23 for0 against
• To ratify the remuneration of M/s Dalwadi & Associates, Cost Accountants for FY 2025-26 of INR 3,70,000 plus applicable Goods and Service Tax, p.a. and reimbursement of all reasonable out of pocket expenses incurred:MoreLess

  23 for0 against
• To Appoint M/s. Ashish Shah & Associates, Company Secretaries as Secretarial Auditors of the company, for a term of five (5) consecutive financial years commencing from financial year 2025-26 to the financial year 2029-30MoreLess

  23 for0 against
• To Approve Granting Loan, giving Guarantee or providing Security in respect of any loan as per section 185 of the Companies Act, 2013

  ›Against Angel One Mutual Fund, Axis Mutual Fund, Bandhan Mutual Fund, Baroda BNP Paribas Mutual Fund, Canara Robeco Mutual Fund, Edelweiss Mutual Fund, Groww Mutual Fund, HDFC Mutual Fund, HSBC Mutual Fund, ICICI Prudential Mutual Fund, Invesco Mutual Fund, Jio BlackRock Mutual Fund, LIC Mutual Fund, Mirae Asset Mutual Fund, Motilal Oswal Mutual Fund, Navi Mutual Fund, Nippon India Mutual Fund, quant Mutual Fund, UTI Mutual Fund

  • Angel One Mutual FundInadequate disclosures regarding the particulars mandated u/s 185 of Companies Act, 2013; Governance Concern: Inadequate disclosures with regards to justification and recipients of the investments, loans, guarantees and security.
  • Axis Mutual Fund, Canara Robeco Mutual Fund, Jio BlackRock Mutual FundThe approval is enabling in nature, and it could allow the company to give loans / guarantees / provide securities to any company in which directors are interested, including promoter companies. The company must disclose granular details including names of these companies and entities, the nature and size of their operations and terms of support, and rationale, to enable shareholders to make an informed decision. Given the lack of clarity, we are unable to support the resolution.
  • Bandhan Mutual Fund, Edelweiss Mutual Fund, Groww Mutual Fund, Motilal Oswal Mutual Fund, Navi Mutual FundNon-compliance concern: Inadequate disclosures regarding the particulars mandated u/s 185 of Companies Act, 2013; Governance Concern: Inadequate disclosures w.r.t justification and recipients of the investments, loans, guarantees and security.
  • Baroda BNP Paribas Mutual FundCompany has not provided sufficient disclosure as to the recipients or justification for use of funds.
  • HDFC Mutual FundThere is a lack of clarity regarding the names of these companies and entities, the nature and size of their operations and terms of support, and rationale, to enable shareholders to make an informed decision. We do not support the resolution.
  • HSBC Mutual FundA vote AGAINST this resolution is warranted since the company may be taking in a disproportionate amount of risk relative to its ownership stake without compelling justification.
  • ICICI Prudential Mutual FundThe approval is enabling in nature, and it could allow the company to give loans / guarantees / provide securities to any company in which directors are interested, including promoter companies. The company must disclose granular details including names of these companies and entities, the nature and size of their operations and terms of support, and rationale, to enable shareholders to make an informed decision. Given the lack of clarity, the AMC has voted against the resolution.
  • Invesco Mutual FundThe approval is enabling in nature, and it could allow the company to give loans / guarantees / provide securities to any company in which directors are interested, including promoter companies. The company must disclose granular details including names of these companies and entities, the nature and size of their operations and terms of support, and rationale, to enable shareholders to make an informed decision. Given the lack of clarity, we are unable to support the resolution
  • LIC Mutual FundGovernance Concern: Inadequate disclosures w.r.t justification and recipients of the investments, loans, guarantees and security.
  • Mirae Asset Mutual FundAs per advisory recommendation (passive holding)
  • Nippon India Mutual FundNon-compliance concern: Inadequate disclosures regarding the particulars mandated u/s 185 of Companies Act, 2013;
  • quant Mutual FundNon-compliance concern: Inadequate disclosures regarding the particulars mandated under section 185 of Companies Act, 2013. Governance concern: Inadequate disclosures w.r.t justification and recipients of the investments, loans, guarantees and security.
  • UTI Mutual FundGiven the lack of clarity, we are unable to support the resolution.

  4 for19 against